BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial

BACKGROUND: Replacement of carmustine (BCNU) in the BEAM regimen (BCNU, etoposide, cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell transplantation (ASCT) is feasible in lymphoma. However, randomised trials are lacking. Here, we present the first trial addressing this...

Descripción completa

Detalles Bibliográficos
Autores principales: Keil, Felix, Müller, Antonia M.S., Berghold, Andrea, Riedl, Regina, Buxhofer-Ausch, Veronika, Schuster, Judith, Vorburger, Corinne, Böhm, Alexandra, Panny, Michael, Nösslinger, Thomas, Greil, Richard, Samaras, Panagiotis, Bencker, Celine, Rütti, Markus, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679477/
https://www.ncbi.nlm.nih.gov/pubmed/38024477
http://dx.doi.org/10.1016/j.eclinm.2023.102318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679477/
https://www.ncbi.nlm.nih.gov/pubmed/38024477
http://dx.doi.org/10.1016/j.eclinm.2023.102318

Ejemplares similares